Skip to main content
IMCR $26.41 -0.83%
IMCR logo
IMCR · Immunocore Holdings plc
Track IMCR — free
$26.41 -0.22 (-0.83%) At close · Nov 20 Q4 2025 earnings call transcript
Market Cap
$1.36B
Shares
51.68M
Volume · Nov 20 546.2K Avg daily vol (3M) 449.07K
All webcasts

Conference · 2026-11-17

Immunocore Holdings plc (IMCR) November 17, 2026 Conference Transcript

Concluded Nov 17, 2026 Audio replay
Nov 17, 2026 29:31 62 turns
Period
2026-11-17
Runtime
29:31
Sources
3 artifacts
Open full screen Slides 50

Transcript & audio

29:31 Audio
Dina Elmanchid Analyst — UBS

Hello, everyone. My name is Dina Elmanchid, one of the biotech analysts here at UBS, and I am excited and pleased to welcome Travis Coy, Chief Financial Officer of Immunocore. I am excited for us to get started on this, and so maybe we can start with a couple of questions around the commercial business for KimTrack. Maybe just, you know, we are probably in our fourth year of launch now, and so given, you know, pretty peak penetration levels in especially OUS market and maybe 70% in the U.S., nearly there. So maybe just thinking about where are the remaining growth drivers, particularly, you know, in the community setting, both in the U.S. and OUS, and where do you see KimTrack from here, you know, in the outer years?

Yeah, no, thanks. First of all, thank you for having me and having us. So all good questions on ChemTrack. We're really pleased that ChemTrack has become the standard of care across all major markets. And you're elaborating to some of the penetration levels we've had. We're at 70% plus penetration across all markets. And so as we look at the growth, naturally in this part of the product's life cycle, we're seeing growth begin to moderate. It's a good thing, right? We did a good job on launch, right?

Dina Elmanchid Analyst — UBS

You launched very quickly. Yeah, we did.

But as we look, we still see opportunities for growth. And there's two different aspects. There's the U.S. and the OUS. From a U.S. perspective, our growth is centered and focused on penetrating further into that community setting, continue to increase patient access in that community setting. O-U-S, our growth mainly comes from new launches. We're 80% to 90% penetrated in some of those markets, so new launches are really where we see the growth, and again, it's increasing that patient access. We also see some growth O-U-S from increasing duration of therapy. So some of the markets where we've more recently launched, that duration of therapy is still ticking up to where it already is in established markets.

Dina Elmanchid Analyst — UBS

Okay. That makes sense. Um, what is the duration of therapy now? I think the last time we've talked about this, maybe around 14 months. Um, what is it looking like now? And, you know, nearly, you know, 20, 27.

Yeah. So, um, and I'll, I'll mention when we are five years on the market now, but that's okay. Um, as we, so as we look at the duration of therapy in the U S it's mostly stabilized. I'd say that's fair to say across the major markets where we've been launched four or five years. We're mostly see the duration of therapy around 14 months. Okay. What's remarkable about that is in the clinical setting, we saw around 10 to 11 months. And I think that's just a testament to the product's profile, right? And it's also what has been allowed us to be as successful as we have been pushing into the community setting because if physicians weren't comfortable with that product profile, weren't comfortable with patients getting benefit, then we wouldn't have reached this duration of therapy that is incredibly rare to see in the real world longer than what we've seen in the clinical study.

Dina Elmanchid Analyst — UBS

I actually want to point the next question about recent data that you presented at a medical conference just a couple of weeks ago, and that was also in uveal melanoma as well, and that was looking at KimTrack plus Preem, if I remember that correctly, and the data actually looked. It's significantly better in a phase one study versus chemtrack monotherapy of what we have today on the market. I believe that you guys are moving that forward into potentially phase two, phase three. Maybe talk about how that is, you know, maybe not something that we're going to see to the long-term or to the near-term growth, but maybe a long-term growth driver as we have, you know, better efficacious medicines with chemtrack and combinations that we can see on the market in uveal melanoma.

Yeah, so we're really excited by that data, and it was interesting. It's not just a testament to us. It's also a testament to investigators and KOLs that we're seeing the data and saying, there's something going on here. And so just to re-summarize the data a little bit, you're exactly right. We saw, and one of the things that's important to note from a biology perspective is that PREM is a negative prognostic in uveal melanoma, so there was very good biologic rationale for doing the combination to start with, but what we saw is... From the very consistent clinical activity across all metrics, and I'll talk about those in a second, as well as no safety, additive safety, the safety profile of the combination was very consistent with the individual components. And so from, and going back, so going back to the clinical activity a little bit, just to highlight some of the numbers we saw, we had ORR of 29% versus monotherapy to Bentafuss of around 11%. We had PFS of 8.1% versus, again, monotherapy to ventafest, but around 3.4. And then a duration of therapy, which is, sorry, a duration of response of 24 months. So, again, across all metrics, almost a doubling, in some cases almost tripling of benefit. And if you look at survival, the two-year overall survival. of the combination was around 70% compared to 45% for KimTrack alone. So despite the innovation that KimTrack has brought to the market of doubling overall survival in five years, obviously there's room to improve. And we think the combination of KimTrack plus Bernanda Fusp is that improvement.

Dina Elmanchid Analyst — UBS

I mean, I thought the data was stunning. I mean, really, it was buried in your press release there in earnings and then presented at the medical conference. So I wanted to highlight that. Maybe one final question on the landscape for uveal melanoma. There is a competitor out there that is filing to the FDA soon with an oral pill. Um, my view and our models, you know, don't reflect any increase in competition, given your medicine is in an HLA positive population. And that's what KimTrack targets, um, versus their medicine is in, um, HLA negative. There are some, you know, data in HLA positive, but my viewpoint and, um, you know, UBS sees that. So, KimTrack should be pretty insulated in terms of our revenues over the next couple of years, given that you guys are the standard of care in first line. It is HLA positive. So, maybe just talk about your expectations on how a new competitor entering the market for the first time in, you know, in five years could impact the base business.

Yeah, so I think, first of all, from our perspective, it's great to see innovation in unmet need. And from, again, our perspective, that unmet need is in HLA-negative patients. If you look at where ChemTrack, as you just alluded to, is a well-established standard of care, and we talked about the penetration rates already that we have, we're going to continue to focus on the value proposition that ChemTrack has brought. Earlier this year, we disclosed our five-year overall survival, and I mentioned there was a doubling of overall survival at five years. Another important aspect in that same data set is that almost half of those patients only received ChemTrack. So it allows us to reinforce that messaging of start with ChemTrack and continue to treat as patients continue to benefit. And that's been something that's very consistent. We've heard from investigators as well. And the last aspect I'll mention is safety, the safety profile that we have with ChemTrack. I talked a bit about the product profile that has allowed us to be successful in the community setting, and safety is certainly part of that because community physicians have to get comfortable with that safety profile, and what you see is a very consistent and manageable safety profile that really, you know, you may see some CRS in the first few doses, but that's on mechanism, and then it goes to very, you know, low single digits of AEs, and we do not see, and we have the five-year overall, data to show it, we do not see any cumulative toxicities. So I think that's very different than what you will often see from a small molecule.

Dina Elmanchid Analyst — UBS

Okay, that makes sense. I guess focusing now and shifting to metastatic melanoma, you, I would say... You have a very interesting catalyst that just recently got pushed, which is the TAB-AM study in second-line metastatic melanoma, where there is maybe two new therapies that have various different uses, to say the least, and are just recently come to market. You are going to have this phase three data. I think it is now being pushed to Q227. And, um, from as early that was potentially going to come this year. So maybe you just talk to us about your confidence in this study in being positive and maybe what is the magnitude of benefit that you would want to see in that, in order for this to be, you know, practice changing in HLA positive second line metastatic melanoma.

Yeah, so there's several aspects that give us confidence in starting a registrational randomized phase 3 study in advanced cutaneous melanoma. And I think the first is, one, it's a life cycle management play for ChemTrack, right? So we've already shown a demonstrated survival benefit in UVL melanoma. So then you might ask, well, what's the consistency between uveal and continuous? And there's a lot of overlapping biology between those two tumors. Namely, the GP100 target that Chemtrek focuses on is incredibly highly expressed in both tumors, 85% plus, right, in both tumors. So there's very good consistency there. And I think the third aspect I'll mention is if you look back at uveal, it was a tumor that was historically immune insensitive, right? A cold tumor, if you will. And if you look at, and so ChemTrack was the first really innovation in that space in like 40 years. And I think if you look at the patient population with which we're studying in advanced cutaneous, these are very refractory patients. They've had to progress on a PD-1 within six months. So in many respects, they reflect that aspect of being cold tumor like where we've seen success with ChemTrack. So I think all those things, including combining. Combining it with one of the arms is chemtract plus pembrolizumab. So combining two active agents that we know are active in cutaneous is all those things contribute to the confidence we have in tebiam.

Dina Elmanchid Analyst — UBS

Okay, great. I guess one follow-up question on that would be, you're enrolling the study globally, of course, but most cutaneous monogamous studies enroll majority OUS, and there's maybe various treatment landscapes for the control arm, and the control arm in this study is actually very unique, and a lot of doctors have actually, in KOLs that we've spoken to, have praised the control arm because it is very ridiculous. It resembles what real life is, which is there's not that many options. So you can either be followed with no treatment, go to a clinical trial, or maybe you have retreatment of chemo. But maybe talk through what are the options that we can expect to see in this control arm and how, you know, given there are so many options one can get, how can we think about That median, you know, OS benefit that we can see in the control arm.

Yeah. So if you look across this line of therapy, so a few things to point out, the trial design such that patients have to have failed ipinevo, so PD-1 plus CTLA-4, and they've also had to have failed a BRAF therapy if they were BRAF mutant eligible. So if you look at that patient population, there's been no therapy that's ever shown an overall survival benefit in a randomized study. So this is a very, obviously, high M at need, which is why, and there's no standard, and as such, there's no standard of care in these patients. So it's why we designed the study, Tebiam, how we did, to allow for locally available therapy in that control arm. So then to your question of what do we expect to see? So if we look across the real-world evidence in this space, despite there not being a standard of care, What we intend to see is roughly, again, roughly, this is going off real-world evidence, we see about a third of some PD-1-based retreatment.

Dina Elmanchid Analyst — UBS

Okay.

Probably 20 to 25 percent BRAF retreatment.

Dina Elmanchid Analyst — UBS

Okay.

And then the rest, unfortunately for patients, being chemo or palliative care, maybe a small number of clinical trials.

Dina Elmanchid Analyst — UBS

Okay.

And then to your earlier question that we get. Relatively frequently, because the trial is largely enrolled in Europe, which is consistent for any current melanoma trial study that's been conducted, we're not going to see those neurotherapies that you alluded to because they're not approved there.

Dina Elmanchid Analyst — UBS

Yeah, no, that makes sense. I guess the most common thing is to retreat or chemo, besides a clinical trial. When you think about retreatment, So PD-1, like IO retreatment is what you're saying maybe one-third of the patients get. So are they just being retreated maybe with Keytruda or Nuvilumab, or are patients also getting, you know, ipinevo as well? Is that also a possibility given the patient population had to have failed and been refractory already to ipinevo to be included in this trial? And so I guess I'm wondering on that because, you know, even if they had failed PD-1, they could still get retreated with it. But if they failed ipinevo, can they also be retreated with it, just given the nature of that there is limited options?

Yeah, they can be. A lot of that will be dictated by what is approved and reimbursed in various countries, right? So I suspect there's going to be a fair amount of PD-1 monotherapy. There'll be some ipinevo, probably retreatment.

Dina Elmanchid Analyst — UBS

Yep.

Um, there'll also probably be some, um, all, all small numbers because, uh, in Europe PD-1 like three is only approved in PD-1 negative.

Dina Elmanchid Analyst — UBS

Right.

So if you, if, from our perspective, you kind of take all those and the best, the best publication we really have is on ipinivo retreatment. It was a retrospective study. I'll be at only 25 patients.

Dina Elmanchid Analyst — UBS

Yeah.

The retreatment on ipinivo when they were 100% PD-1 CTLA-4 treated previously. It was truly a retreatment of the same regimen was around nine to 10 months. But if you look across kind of all that blend and including everything else I mentioned, chemo, unfortunately, chemo is shown to only, it's not very effective. It's only shown to be about six months. So if you take a blend of all those segments that I mentioned earlier, we're expecting about 10 to 11 months in the control arm.

Dina Elmanchid Analyst — UBS

And then your drug arm in the phase two that was done many years ago, you know, that's what I think around 16 to 18 months, depending on the different subgroups. And, you know, that was done, I think, conducted maybe a couple years ago, and it was not in combination with Keytruda, but in combination with... So, my question then, I think Kachuda is obviously a stronger, you know, PD-1 regimen. Would you expect that maybe there is, you know, the drug arm or the combination arm in your study in TABIM could maybe do a little bit better than you had originally seen, just given the difference in that combination with Kachuda versus Diverlemab?

Uh, maybe there's potential for that. I wouldn't say that's our base expectation. I think we feel strongly that if we recapitulate the roughly 60 patients that you're alluding to earlier in phase one, we'll feel. Confident in the outcome of the study.

Dina Elmanchid Analyst — UBS

Okay, great. What do you think is clinically meaningful? I mean, some of the KOLs that we've talked to at ASCO say, you know, a delta of, you know, maybe two to three month difference on OS is as much as clinically meaningful. You know, that's as long as we, you know, has a ratio of 0.8, you know, would be something that would change the practice, just given that there is limited options. How are you guys thinking about what is a clinically meaningful result for the study?

So we haven't disclosed the details of the statistical analysis plan, but what I'll anchor back to is there's been no therapy that's been able to show an overall survival benefit in this patient population. So if we were able to show that statistically significant overall survival benefit, we feel good about our... Commercial aspects.

Dina Elmanchid Analyst — UBS

Okay, great. So this data is going to come in Q2. Q2. So are we thinking that that could maybe be early Q2, mid Q2, late Q2? What are we thinking? Is this going to be a late breaker at ASCO next year? Should we book our hotels and flights already? They get pretty expensive. Or how should we think about that?

We sure hope all that comes true. Yes, feel free. No, in all seriousness, it's an overall survival-driven endpoint. So we have to leave ourselves wiggle room. So I think it's best to stick to Q2 at this point.

Dina Elmanchid Analyst — UBS

So we did some analysis recently, and our take is on the margin, having this pushed out from late this year into Q2 next year is maybe a little bit positive because that could suggest that events are taking a little bit longer to accrue. And so that means that there is maybe, you know, patients are surviving longer, correct, especially on the combination arm, which would be the most logical explanation given we have a pretty good understanding of how long patients last on the control arm. What do you guys make of that? You know, are we on the right track, or should we rethink our analysis?

Yeah, first and foremost, we can't see the data, right? I need to make that, obviously make that comment. And it's blinded. So for the integrity of the trial, we can't see the data. That being said, let me give you a little more insight as to what I'll call shift in timing. We were previously saying as early as the end of the year, really reflecting a couple of things. One, that's an overall survival-driven endpoint. There's flexibility with that. We also hadn't completed enrollment yet. So we completed an enrollment last quarter, and that gave us more specific insight into how those events were accruing from an independent stats group. So I wouldn't read too much into the shift in timing. I'd more reflect it as better data and pointing to Q2 versus as early as the end of the year.

Dina Elmanchid Analyst — UBS

Okay. Got it. Maybe then shifting to the remaining oncology pipeline, we've just hit on basically the base business, the next near-term catalyst, which is Tebby AM. You have a big, large, actually, first-line melanoma frame program that's ongoing. I know this is a little bit more further out. The data initially, I think, was a little bit confusing for investors in Wall Street. Maybe just thinking through... This is still enrolling now, and it takes about three years to enroll, and I believe this was started enrolling in 2024 is when I believe I was at ASCO, and I remember Bahija telling me that we just enrolled our first patient. So I want to say that we could probably get to 2027. Can we expect enrollment to complete around then, or how should we think about that, and if you can guide to anything about the PREM studies?

Yeah, happy to. So the study is referred to as PRISM-MEL. So this is a frontline cutaneous melanoma study with... Brenetta FUSP plus Nivolumab versus a Nivolumab-based regimen. And so enrollment's been going very well. We are on track to complete enrollment in 2027. And it's always encouraging to see enrollment go very well. I think the other aspect I'll say is some of the confidence you're alluding to, what gave us the confidence to run the registrational trial. And I think it's a multitude of things. One is... One, we generated and saw good activity in Brunetifest as a monotherapy. I think that's an important thing to mention. Yes, it was in a later line of cutaneous melanoma, but seeing that monotherapy data, and if you look at the disease control rate as a monotherapy, it exceeded the combination of NEVO-LAG3, for example, where I think we're all curious as to kind of come to the conclusion that LAG3 didn't have any monotherapy activity. Despite, at least to my knowledge, they're not having published it. So that gave us, and that combined with the aspect that we know from our T-cell, right, driven platform, that moving into earlier lines, you have healthier T-cell fitness. And so combining those two things combined with then... Given the experimental arm with Brunetta Fuss is plus nivolumab, so you have two distinct mechanisms of action that... You know, from our base case, or if you will, have at least a minimum of an added effect, potentially even a synergistic effect. So you take all those things combined, and that's sort of what gives us the confidence in PRISMO.

Dina Elmanchid Analyst — UBS

No, that makes sense. I guess, so it sounds like you guys are on track to enroll in, or finish enrollment in 2027. Rough estimate, and obviously I know you guys haven't guided to. Would be premature to, but maybe just thinking about how long in a history, you know, in a first line, when you look at the Abdullak studies, how long does it take to a PFS endpoint in, you know, just looking at historical first line melanoma trials?

Yes, correct. It is a primary endpoint is PFS and somewhere between right now we're saying somewhere between six and 10 months. So sometime in 2028. Okay, got it.

Dina Elmanchid Analyst — UBS

Okay, great. So that's another catalyst to look forward to. And to be honest, 2020, it's not that far away. Okay, great. I did notice that in your recent update on moving from oncology, moving on to... And HIV, actually, which I think is a very interesting space. Maybe just thinking about you were supposed to have an update with the higher doses later this year, but that also got moved to next year. Talk through why that was pushed out, what you're waiting to see, and what we're expecting to happen with that program, and maybe just refresh us on the data. It is quite an interesting program, and I think you guys don't—maybe it's a little bit under the radar, given everyone's focus on oncology, but maybe just talk through that a bit.

Yeah, so I think our efforts in both infectious disease and autoimmune speak to the modularity of the platform, right? So this allows us to change out various components of the bispecific to then address other T cell-mediated diseases. And so one of the things we're looking for in infectious disease—this is a high bar. We're looking to achieve a functional cure. That is the intent around the HIV program. So we saw Encourage initially, which we disclosed at CROI in 2025. I had to get my years correct.

Dina Elmanchid Analyst — UBS

Yeah, I think it was 25. March 2025, I remember where I was exactly.

We had encouraging signs of antiviral activity, but we wanted to further optimize and further demonstrate even additional activity. So we continue to dose escalate. We did not hit any dose limiting toxicities. So we continue to take those doses higher. So what we've recently... What we've been able to achieve is we've now taken that platform up to 1,200 micrograms. It's actually higher than we had gone in any previous aspects of the platform and continue to see good safety. So what we'll be looking to disclose next year at a medical conference that I can't name quite yet is to disclose that activity.

Dina Elmanchid Analyst — UBS

Okay, great. So we'll be at a medical conference, presumably one where HIV data is presented. There's two of them, so I'll look forward to that.

A couple of them.

Dina Elmanchid Analyst — UBS

A couple of them, but two big ones. But not many, yes. So I look forward to that data. It's interesting you brought in your INI portfolio, which I actually think is even more under the radar than HIV. And actually, I was talking to a couple of investors, and they brought it up a couple months ago. So you have a PD-1 agonist that you guys are taking forward into the clinic, I think, this year. Walk us through that. I believe it is going with type 1 diabetes and then maybe potentially atopic dermatitis. But you haven't really talked much about that. So maybe, you know, in the last five minutes or so, talk about what your strategy is for Immunicore. You know, INI is a pretty big space, multi-blockbuster, and there's many different indications that you can go in. Maybe talk through what is the strategy from Unicor from and the assets that you guys currently have in development.

Yeah, I'm really excited that we've gotten this underway. So we dosed our first patient with type 1 diabetes last quarter. And this goes back to that modularity of the platform that I was referring to. So our strategy on the autoimmune side is to take what we've learned in oncology and apply it to immunology. And specifically, the aspect I mean from that is we are able to deliver very specifically to the tumor in oncology. We've now been able to demonstrate that. We believe we can do the same thing in immunology and have a tissue-specific approach, right? So to talk about the type 1 diabetes program in a little more detail. The bispecific that we've designed for type one has two components. It's a pre-pro insulin targeting. Pre-pro insulin is expressed explicitly in beta cells in the pancreas. So think of that as the targeting aspect of the bispecific. The other side, as you alluded to, is a PD1 agonist. We know type one diabetes is a almost purely T cell mediated and driven disease. So the intent is to stop the T cells by. By the PD-1 agonism to stop the T cells from attacking the beta cells and therefore preserving insulin production. So it's something we're incredibly excited about because I think, and if this is a proof of concept, if you will, for autoimmune and being tissue specific, because if we're able to show this tissue specific aspect of downregulating the immune system, it opens up a plethora of other opportunities for us. And so the single sending dose is underway. Another thing that I like from the CFO perspective is this is a very capital-efficient program, meaning we will be able to get data from the SAD and the MAD that gives us confidence in moving forward, assuming the data looks good. And to give you a little more sense of what I'm talking about there is single ascending dose, we'll really be looking for PD-1. We're looking for target engagement and therefore looking for soluble PD-1 and making sure there's an increase in soluble PD-1. That gives us confidence in the target engagement. Assuming we see that, we'll move to the multiple ascending dose where we can look at C-peptide. C-peptide is an approvable endpoint, as demonstrated by tepluzumab. And so we'll be able to see C-peptide data in the multiple ascending dose data because the phase one is being run in people with type 1 diabetes. And so that gives us, you know, that allows us for a very efficient manner to see clinical activity in a short amount of time.

Dina Elmanchid Analyst — UBS

Yeah.

Um, so we, you know, we'll, it's underway.

Dina Elmanchid Analyst — UBS

Okay.

Um, maybe a little too early to comment on when we expect to have results because we've only dosed the first patient so far.

Dina Elmanchid Analyst — UBS

Yeah.

Um, but, but stay tuned. We'll, we'll obviously update on timing as soon as we can.

Dina Elmanchid Analyst — UBS

It was interesting when we had met in your offices in, um, just here, actually the headquarters in England, um, a couple of years ago, I believe that you guys were talking about maybe getting initial data and then maybe partnering Is that still the case, or would you guys develop this in-house if you did see good C-peptide data and good target engagement in the SADMAD? Would you move this forward? I mean, it's not like you need to go out and raise a lot of money to take this forward. You guys are pretty well capitalized, but how are you thinking about that?

Yeah, we are well capitalized with just over $900 million of cash on the balance sheet. But we also want to be good stewards and efficient with that capital. So if you look at where we're most established, it's in oncology, right? We have a development and commercial footprint in oncology. So I think it's logical to say, as you look at autoimmune and infectious disease, we'll likely to take those two inflection points and then look for partners that have more established presence there.

Dina Elmanchid Analyst — UBS

Okay.

So it's more of a timing thing. The value inflection we think we can generate with efficient capital, as I alluded to in those areas, is strong. And then from there, we'll probably look for someone else to help maximize value in those programs.

Dina Elmanchid Analyst — UBS

Okay. Have you started, obviously, with INI way too early? We're still not even gotten the data, but we've seen good data so far with HIV. Would you say that you've had conversations and you're just waiting on additional data to engage more with partners, or how should we think about that?

Yeah, it's fair to say from a business development perspective, you're always having those conversations, right? Because you're always looking for opportunities. So it's fair to say that's just a consistent thing we do as part of the business.

Dina Elmanchid Analyst — UBS

Well, you know, there are two key HIV players, and one of them is in this country. So just, you know. Well, I think that's all the time we have for today. Thank you so much for taking this time to talk through this. I thought it was very insightful, and thank you again.

Thank you again for having us. Appreciate it.

Analyst Q&A · 1 question
Full-screen source Call document